bcbs glp-1 coverage Drugs: What Employers Need to Know Blue Cross Blue Shield of
Description
The substantial weight loss achieved with GLP-1 receptor agonists and dual GIP/GLP-1 agonistsapproximately 15% with semaglutide 2.4 mg (Wegovy) and up to 21% with higher doses of tirzepatide (Zepbound) in clinical trialsoccurs primarily through appetite suppression and reduced caloric intake rather than increased metabolic rate
doi: 10.2337/dci23-0048
[DOI] [PMC free article] [PubMed] [Google Scholar] 48.Qin C, Li J, Tang K
It was one of the first medications designed to tackle not just physical hunger, but emotional and habitual eating too
The WHO recommends only at 30
